Randox QC centralized platform, 7/17
July 2017—Randox Quality Control launched a centralized platform for the management of daily quality control activities
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
FDA 510(k) clearance for BD FACSVia, 7/17
July 2017—Becton Dickinson received 510(k) clearance from the FDA for its BD FACSVia, a flow cytometer system with a leucocount reagent assay used in residual white blood cell enumeration.
Siemens, Relaymed deal, 7/17
July 2017—Siemens Healthineers announced a strategic alliance with Relaymed to bring customers secure, cloud-based connectivity for Siemens DCA Vantage analyzer and Clinitek Status point-of-care instruments.
QC product for blood bank testing, 7/17
July 2017—Hemo Bioscience announced its MQC-CAT—a ready-to-use quality control product for manual column agglutination technology blood bank testing methods—has received FDA 510(k) clearance.
Helomics, MDNA launch prostate test, 7/17
July 2017—Helomics and MDNA Life Sciences announced the commercial launch of MDNA’s liquid biopsy Prostate Mitomic Test in select U.S. markets. The proprietary test, which utilizes MDNA’s Mitomic Technology platform, uses the unique biological characteristics of mitochondrial DNA and is available in the clinical laboratories of Helomics.
ClearLight, Indiana University collaboration, 7/17
July 2017—ClearLight Diagnostics has signed a collaboration agreement with the Indiana University Melvin and Bren Simon Cancer Center to study the tumor microenvironment in patients with breast cancer.
Quest acquires two Texas labs, 7/17
July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.
Distribution partnership for SpeeDx, Cepheid, 7/17
July 2017—SpeeDx announced an agreement with Cepheid for distribution of its PlexPCR and ResistancePlus molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the U.K., will increase coverage for the ResistancePlus MG test, a CE-IVD test for the sexually transmitted infection Mycoplasma genitalium that combines detection with testing for azithromycin resistance.
OpGen, Thermo Fisher supply agreement , 7/17
July 2017—OpGen has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help health care providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.
Infectious diseases monoclonal antibodies, 7/17
July 2017—The Binding Site’s Immunologicals Group has completed a major expansion to its monoclonal antibody product offerings. In addition to the company’s conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, a number of monoclonal antibodies focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma have been introduced.